MCID: ESP027
MIFTS: 35

Esophagus Squamous Cell Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 12 15
Squamous Cell Carcinoma of Esophagus 12 73
Esophageal Squamous Cell Carcinoma 44
Scc of Esophagus 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3748
MeSH 44 C562729
NCIt 50 C4024
SNOMED-CT 68 276804009
UMLS 73 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Disease Ontology : 12 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

MalaCards based summary : Esophagus Squamous Cell Carcinoma, also known as squamous cell carcinoma of esophagus, is related to squamous cell carcinoma and esophageal cancer. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR145 (MicroRNA 145
miR-145 directly regulate FSCN1, which is widely expressed by mesenchymal tissues and in the nervous system, and contribute to cellular proliferation and invasion in esophageal squamous cell carcinoma (ESCC).), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Aspirin and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include the esophagus, lymph node and lung.

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 29.1 HOTAIR LINC01233 TUG1
2 esophageal cancer 11.2
3 functionless pituitary adenoma 10.5 HOTAIR MEG3
4 gastric cardia adenocarcinoma 10.4 HOTAIR MEG3
5 pituitary adenoma 10.4 HOTAIR MEG3
6 ovarian epithelial cancer 10.4 HOTAIR MEG3
7 kidney cancer 10.3 HOTAIR MEG3
8 esophagus adenocarcinoma 10.2 AFAP1-AS1 MIR145
9 clear cell renal cell carcinoma 10.2 MEG3 MIR145 TUG1
10 lung squamous cell carcinoma 10.1 MEG3 NPTN-IT1 TUG1
11 bladder urothelial carcinoma 10.0 HOTAIR MEG3 TUG1
12 myeloma, multiple 10.0 HOTAIR MEG3 TUG1
13 colorectal adenocarcinoma 9.8
14 adenocarcinoma 9.8
15 lymphopenia 9.8
16 glioma 9.8 HOTAIR MEG3 MIR296
17 renal cell carcinoma, nonpapillary 9.8 HOTAIR NPTN-IT1 TUG1
18 thyroid cancer, nonmedullary, 1 9.8 BANCR HOTAIR MEG3
19 pancreatic ductal adenocarcinoma 9.8 AFAP1-AS1 HOTAIR MIR145
20 retinoblastoma 9.7 BANCR HOTAIR MEG3
21 glioblastoma 9.7 HOTAIR MEG3 MIR296 TUG1
22 leukemia, acute myeloid 9.7 HOTAIR MEG3 TUG1
23 gastrointestinal system cancer 9.7 BANCR HOTAIR
24 cervical cancer 9.6 HOTAIR MEG3 NPTN-IT1 TUG1
25 tongue squamous cell carcinoma 9.5 AFAP1-AS1 MEG3
26 osteogenic sarcoma 9.4 BANCR HOTAIR MEG3 TUG1
27 oral squamous cell carcinoma 9.4 HOTAIR MEG3 MIR145 MIR296 TUG1
28 nasopharyngeal carcinoma 9.4 AFAP1-AS1 HOTAIR MEG3 NPTN-IT1
29 prostate cancer 9.1 HOTAIR MEG3 MIR145 MIR296 TUG1
30 bladder cancer 9.1 BANCR HOTAIR MEG3 MIR145 TUG1
31 pancreatic cancer 9.1 AFAP1-AS1 HOTAIR MEG3 TUG1
32 gallbladder cancer 9.0 AFAP1-AS1 HOTAIR MEG3 NPTN-IT1 TUG1
33 adamantinoma of long bones 9.0 AFAP1-AS1 HOTAIR MEG3 NPTN-IT1 TUG1
34 lung cancer susceptibility 3 9.0 AFAP1-AS1 HOTAIR MEG3 NPTN-IT1 TUG1
35 ovarian cancer 8.9 AFAP1-AS1 HOTAIR MEG3 MIR296 TUG1
36 lung cancer 8.2 AFAP1-AS1 BANCR HOTAIR MEG3 MIR145 TUG1
37 hepatocellular carcinoma 8.0 AFAP1-AS1 BANCR HOTAIR MEG3 MIR145 NPTN-IT1
38 colorectal cancer 7.7 AFAP1-AS1 BANCR HOTAIR MEG3 MIR145 MIR296
39 gastric cancer 7.0 AFAP1-AS1 BANCR CTD-3080P12.3 HOTAIR MEG3 MIR145

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
2
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
5
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
6
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1 205923-56-4 56842117 2333
7
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
8
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
9
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
10
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
11
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
12
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
13
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
14
Vinblastine Approved Phase 3 865-21-4 13342 241903
15
Vinorelbine Approved, Investigational Phase 3,Phase 2 71486-22-1 60780 44424639
16
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
17
nivolumab Approved Phase 3,Phase 1,Phase 2 946414-94-4
18
Trioxsalen Approved Phase 3 3902-71-4 5585
19
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
22
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
23
Caffeic acid Experimental, Investigational Phase 3 331-39-5 1549111
24 Analgesics Phase 3,Phase 2
25 Analgesics, Non-Narcotic Phase 3,Phase 2
26 Anti-Inflammatory Agents Phase 3,Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
28 Antipyretics Phase 3
29 Antirheumatic Agents Phase 3,Phase 2
30 Cyclooxygenase Inhibitors Phase 3,Phase 2
31 Fibrinolytic Agents Phase 3
32 Peripheral Nervous System Agents Phase 3,Phase 2
33 Platelet Aggregation Inhibitors Phase 3
34 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
35
s 1 (combination) Phase 3,Phase 2
36 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
37 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
40 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
41 Micronutrients Phase 2, Phase 3,Phase 1,Not Applicable
42 Trace Elements Phase 2, Phase 3,Phase 1,Not Applicable
43 Vitamin B Complex Phase 2, Phase 3,Phase 1
44 Vitamins Phase 2, Phase 3,Phase 1
45 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
46 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Antidotes Phase 2, Phase 3,Phase 1
48 Hematinics Phase 2, Phase 3,Phase 1
49 Protective Agents Phase 2, Phase 3,Phase 3,Phase 1
50 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy;chemotherapy
2 Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols Unknown status NCT01496521 Phase 3 Aspirin
3 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Unknown status NCT01398449 Phase 3
4 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
5 Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
6 Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer Unknown status NCT00509561 Phase 2, Phase 3 capecitabine;cisplatin
7 Surgery With or Without Chemotherapy in Treating Patients With Stage II or Stage III Cancer of the Esophagus Completed NCT00002897 Phase 3 cisplatin;fluorouracil
8 Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer Completed NCT00047112 Phase 3 cisplatin;fluorouracil
9 Surgery or Chemoradiation for Esophageal Cancer Completed NCT01032967 Phase 3
10 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
11 Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus Completed NCT00003118 Phase 3 cisplatin;fluorouracil
12 Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer Completed NCT00861094 Phase 2, Phase 3 cisplatin;5-FU;oxaliplatin;Folinic Acid
13 Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Completed NCT01243398 Phase 3
14 Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
15 Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02399306 Phase 3 nutrison;Docetaxel, cisplatin
16 Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma Recruiting NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
17 A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03430843 Phase 3 BGB-A317;Paclitaxel, or Docetaxel, or Irinotecan
18 A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer Recruiting NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
19 A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma Recruiting NCT02570893 Phase 3 Paclitaxel and carboplatin
20 Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma Recruiting NCT02395705 Phase 3 cisplatin and paclitaxel
21 A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Recruiting NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
22 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
23 Improve the Treatment of Thoracic Esophageal Cancer Recruiting NCT01137123 Phase 3 adjuvant chemotherapy
24 Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer Recruiting NCT02607540 Phase 3
25 Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer Recruiting NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
26 The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy Recruiting NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
27 Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine;Cisplatin
28 Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma; Recruiting NCT01745107 Phase 3
29 Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer Recruiting NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
30 Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma Recruiting NCT02644408 Phase 3 Megestrol(Yining)
31 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Recruiting NCT02603159 Phase 3 Capecitabine(Aibin)
32 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer Recruiting NCT02813967 Phase 3 S-1
33 Robot Assisted Thoraco-Laparoscopic Esophagectomy Versus Conventional Thoraco-Laparoscopic Esophagectomy Recruiting NCT03094351 Phase 3
34 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin Recruiting NCT03143153 Phase 3 Cisplatin;Fluorouracil
35 Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer Recruiting NCT02556762 Phase 3 PF
36 Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer Recruiting NCT03099382 Phase 3 Docetaxel;Irinotecan
37 Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Recruiting NCT02628665 Phase 3 photosensitizer(photofrin)
38 A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma Active, not recruiting NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
39 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181) Active, not recruiting NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
40 Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer Active, not recruiting NCT01216527 Phase 3
41 Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Active, not recruiting NCT01107639 Phase 3 cisplatin;docetaxel
42 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Active, not recruiting NCT00655876 Phase 3 cetuximab;cisplatin;paclitaxel
43 The Efficacy and Safety of Caffeic Acid for Esophageal Cancer Enrolling by invitation NCT03070262 Phase 3 CA;placebo group
44 Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin Not yet recruiting NCT03273647 Phase 3
45 Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC Not yet recruiting NCT03001596 Phase 3
46 Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma Suspended NCT02272699 Phase 2, Phase 3 Nimotuzumab;Paclitaxel;Cisplatin
47 Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer Terminated NCT01627379 Phase 3 Cisplatin, 5-FU;Panitumumab
48 Role of Esophagectomy in Complete Responders to CCRT Terminated NCT01740375 Phase 3
49 A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma Terminated NCT00190554 Phase 3 Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2;(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2+Surgery
50 RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus Terminated NCT00559351 Phase 3 neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagus Squamous Cell Carcinoma:

19
The Esophagus

MalaCards organs/tissues related to Esophagus Squamous Cell Carcinoma:

41
Lymph Node, Lung, Endothelial, T Cells, Breast, Liver

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show all 28)
# Title Authors Year
1
Targeting Orai1-mediated store-operated calcium entry by RP4010 for anti-tumor activity in esophagus squamous cell carcinoma. ( 29908962 )
2018
2
Endoscopic diagnosis and management of early squamous cell carcinoma of esophagus. ( 28815064 )
2017
3
Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway. ( 26831667 )
2016
4
Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. ( 26814381 )
2016
5
Amplification and overexpression of CTTN and CCND1 at chromosome 11q13 in Esophagus squamous cell carcinoma (ESCC) of North Eastern Chinese Population. ( 27877079 )
2016
6
Genotypes of CYP1A1,a88SULT1A1 and SULT1A2 and risk of squamous cell carcinoma of esophagus: outcome of a case-control study from Kashmir, India. ( 26455829 )
2016
7
MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus. ( 26711784 )
2016
8
Diagnostic and prognostic potential of miR-21, miR-29c, miR-148 and miR-203 in adenocarcinoma and squamous cell carcinoma of esophagus. ( 25928282 )
2015
9
Leu432Val Polymorphism of CYP1B1 is Not Associated with Squamous Cell Carcinoma of Esophagus--a Case-Control Study from Kashmir, India. ( 26225675 )
2015
10
Role of postoperative radiotherapy for microscopic margin involvement in the squamous cell carcinoma of esophagus. ( 24155679 )
2013
11
Prognostic Value of Tumor-Infiltrating Mast Cells in Outcome of Patients with Esophagus Squamous Cell Carcinoma. ( 24091743 )
2013
12
Human papillomavirus types 16 and 18 in esophagus squamous cell carcinoma: a meta-analysis. ( 23916383 )
2013
13
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. ( 23409141 )
2013
14
Dermatan sulfate is involved in the tumorigenic properties of esophagus squamous cell carcinoma. ( 22350411 )
2012
15
Prediagnostic smoking and postoperative survival in lymph node-negative esophagus squamous cell carcinoma patients. ( 22913634 )
2012
16
[A multi-centered randomized controlled study of neo-adjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of esophagus: an interim analysis]. ( 22781642 )
2012
17
Downregulation of tropomyosin-1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation. ( 22965424 )
2012
18
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy. ( 23098537 )
2012
19
Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. ( 22234069 )
2011
20
Mimicry of physiological urinary FDG excretion: squamous cell carcinoma of esophagus metastasizing to psoas muscle. ( 21157206 )
2011
21
MDM2 is overexpressed and regulated by the eukaryotic translation initiation factor 4E (eIF4E) in human squamous cell carcinoma of esophagus. ( 21080085 )
2011
22
Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus. ( 19582507 )
2009
23
[Transforming growth factor beta1 regulation of epithelial-mesenchymal transition in esophagus squamous cell carcinoma]. ( 19094466 )
2008
24
Choriocarcinoma - a rare association with squamous cell carcinoma of esophagus. ( 16567899 )
2006
25
[The effect of postoperative chemotherapy after esophagectomy on the survival rate to patients with original squamous cell carcinoma of esophagus]. ( 15231207 )
2004
26
Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. ( 7912679 )
1994
27
Prognostic value of DNA ploidy in squamous cell carcinoma of esophagus. Analyzed with improved flow cytometric measurement. ( 8364859 )
1993
28
Tumor markers in squamous cell carcinoma of esophagus: immunometric assay in cytosol and membrane fraction. ( 2230354 )
1990

Variations for Esophagus Squamous Cell Carcinoma

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

Pathways related to Esophagus Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 HOTAIR MEG3

GO Terms for Esophagus Squamous Cell Carcinoma

Sources for Esophagus Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....